Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
8(80.0%)
Phase 1
2(20.0%)
10Total
Early Phase 1(8)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT06273852Early Phase 1Completed

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

Role: collaborator

NCT06366451Early Phase 1Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Role: lead

NCT06413095Early Phase 1Completed

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Role: lead

NCT04541108Early Phase 1Recruiting

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Role: lead

NCT06062602Early Phase 1Completed

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Role: lead

NCT04065555Early Phase 1Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Role: lead

NCT04891718Early Phase 1Withdrawn

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

Role: lead

NCT04272333Early Phase 1Terminated

Intratumoral Microdosing of Motolimod in HNSCC

Role: lead

NCT03056599Phase 1Completed

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Role: lead

NCT01831505Phase 1Completed

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Role: lead

All 10 trials loaded